Table 4.

Grade 3 to 4 treatment-related adverse effects in 144 nasopharyngeal cancer receiving concurrent chemoradiotherapy, stratified by dipeptiven.

	Dipeptiven (+) N = 41	Dipeptiven (–) N = 103	p
Hematologic events, n (%)
Neutropenia	1 (2%)	16 (16%)	0.02
Febrile neutropenia	0 (0%)	4 (4%)	0.20
Anemia	1 (2%)	8 (8%)	0.23
Non-hematologic events, n (%)
Fatigue	3 (7%)	25 (24%)	0.02
Anorexia	2 (5%)	15 (15%)	0.08
Diarrhea	0 (0%)	1 (1%)	0.52
Vomiting	3 (7%)	8 (8%)	0.92
Oral mucositis	2 (5%)	21 (20%)	0.02
Hearing impairment	0 (0%)	2 (11%)	0.36
Peripheral neuropathy	1 (4%)	12 (22%)	0.03